keyword
MENU ▼
Read by QxMD icon Read
search

radium 223 cancer

keyword
https://www.readbyqxmd.com/read/29340160/stereotactic-body-radiation-therapy-for-the-treatment-of-oligoprogression-on-androgen-receptor-targeted-therapy-in-castration-resistant-prostate-cancer
#1
Thu-Cuc Nguyen, Ravneet Bajwa, Shahla Bari, Azka Ali, William Paul Skelton, Roland-Austin Federico, Rohit Bishnoi, Justin W Wray, Robert A Zlotecki, Long H Dang, Jameel Muzaffar
Castration-resistant prostate cancer is an incurable disease. To date, six agents-abiraterone, enzalutamide, docetaxel, cabazitaxel, radium-223 and sipuleucel-T- have shown clinical efficacy in phase III clinical trials, leading to their FDA approval. Patients are typically sequenced through most or all of these agents, and then eventually succumb to their disease. Development of new treatments remains an unmet need. We report a case of a patient who progressed on enzalutamide with a single enlarging metastatic lesion, was treated with ablative stereotactic body radiation therapy while maintaining the same systemic treatment, who then had durable complete remission...
January 2018: Oxford Medical Case Reports
https://www.readbyqxmd.com/read/29333469/utility-of-f-18-fdg-pet-ct-for-detection-of-bone-marrow-metastases-in-prostate-cancer-patients-treated-with-radium-223
#2
Kaoru Maruyama, Keita Utsunomia, Takahiro Nakamoto, Shigenari Kawakita, Takashi Murota, Noboru Tanigawa
A 76-year-old man with symptomatic bone metastases from castration-resistant prostate cancer underwent Radium-223-dichloride (Ra-223) therapy. Before Ra-223 therapy, he had normal peripheral blood cell counts. Ra-223 therapy relieved his shoulder and low back pain. The elevation of the serum prostate-specific antigen (PSA), doubling every month during Ra-223 therapy, suggested a PSA flare or relapse. Some lesions showed decrease and some lesions showed increase on Tc-99m hydroxymethylene diphosphonate bone scintigraphy at two weeks after the third injection of Ra-223 therapy...
2018: Asia Oceania Journal of Nuclear Medicine & Biology
https://www.readbyqxmd.com/read/29302922/correction-to-dutch-economic-value-of-radium-223-in-metastatic-castration-resistant-prostate-cancer
#3
Michel L Peters, Claudine de Meijer, Dirk Wyndaele, Walter Noordzij, Annemarie M Leliveld-Kors, Joan van den Bosch, Pieter H van den Berg, Agni Baka, Jennifer G Gaultney
The article Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer, written by Michel L. Peters, Claudine de Meijer, Dirk Wyndaele, Walter Noordzij, Annemarie M. Leliveld-Kors, Joan van den Bosch, Pieter H. van den Berg, Agni Baka, Jennifer G. Gaultney was originally published electronically on the publisher's internet portal (currently SpringerLink) on 2nd September, 2017 without open access.
January 4, 2018: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/29298991/current-approaches-to-incorporation-of-radium-223-in-clinical-practice
#4
REVIEW
Chris Parker, Axel Heidenreich, Sten Nilsson, Neal Shore
BACKGROUND: Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), oral hormonal therapies targeting the androgen receptor axis (e.g., enzalutamide and abiraterone), and targeted alpha therapy (e.g., radium-223 dichloride (radium-223)). Although treatment guidelines have been updated to reflect the availability of new agents, it is not easy to apply them in daily clinical practice because recommendations vary depending on patient comorbidities and disease characteristics...
January 3, 2018: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/29287968/dna-repair-pathway-alterations-in-metastatic-castration-resistant-prostate-cancer-responders-to-radium-223
#5
Jorge D Ramos, Elahe A Mostaghel, Colin C Pritchard, Evan Y Yu
No abstract text is available yet for this article.
December 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29286005/current-concepts-and-trends-in-the-treatment-of-bone-metastases-in-patients-with-advanced-prostate-cancer
#6
REVIEW
Miriam Hegemann, Moritz Maas, Steffen Rausch, Simon Walz, Jens Bedke, Arnulf Stenzl, Tilman Todenhöfer
Bone metastases have a major impact on quality of life and survival of patients with advanced prostate cancer. In the last decade, the development and approval of substances inhibiting the vicious cycle of bone metastases have enabled the reduction of complications caused by bone metastases in patients with castration-resistant prostate cancer. These drugs have raised awareness of the importance of skeletal-related events which in the meantime represent an important end point also in trials using agents not specifically designed for bone lesions...
December 29, 2017: Asian Journal of Andrology
https://www.readbyqxmd.com/read/29275145/taxane-based-combination-therapies-for-metastatic-prostate-cancer
#7
REVIEW
Paul G Corn, Neeraj Agarwal, John Charles Araujo, Guru Sonpavde
CONTEXT: Multiple single-agent therapies improving survival are approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC), including two chemotherapies, two androgen-signaling axis-targeting agents, an immunotherapeutic vaccine, and a radiopharmaceutical. Combination therapy can target multiple oncogenic pathways simultaneously, while potentially curbing the development of treatment resistance. OBJECTIVE: To provide a succinct overview of taxane-based combination therapies currently being evaluated for the treatment of metastatic prostate cancer...
December 20, 2017: European Urology Focus
https://www.readbyqxmd.com/read/29243019/evaluation-of-bone-metastatic-burden-by-bone-spect-ct-in-metastatic-prostate-cancer-patients-defining-threshold-value-for-total-bone-uptake-and-assessment-in-radium-223-treated-patients
#8
Takuro Umeda, Mitsuru Koizumi, Shohei Fukai, Noriaki Miyaji, Kazuki Motegi, Shuto Nakazawa, Tomohiro Takiguchi
OBJECTIVES: To establish a new three-dimensional quantitative evaluation method for bone metastasis, we applied bone single photon emission tomography with computed tomography (SPECT/CT). The total bone uptake (TBU), which measures active bone metastatic burden, was calculated as the sum of [mean uptake obtained as standardized uptake value (SUV) above a cut-off level] × (the volume of the lesion) in the trunk using bone SPECT/CT. We studied the threshold value and utility of TBU in prostate cancer patients treated with radium-223 (Ra-223) therapy...
December 14, 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/29241166/the-clinical-efficacy-of-radium-223-for-bone-metastasis-in-patients-with-castration-resistant-prostate-cancer-an-italian-clinical-experience
#9
Rossella De Luca, Renato Patrizio Costa, Vincenzo Tripoli, Alessandra Murabito, Giuseppe Cicero
BACKGROUND/AIM: Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. SUBJECTS AND METHODS: In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated...
December 15, 2017: Oncology
https://www.readbyqxmd.com/read/29234845/eanm-guideline-for-radionuclide-therapy-with-radium-223-of-metastatic-castration-resistant-prostate-cancer
#10
Thorsten D Poeppel, Daria Handkiewicz-Junak, Michael Andreeff, Alexander Becherer, Andreas Bockisch, Eva Fricke, Lilli Geworski, Alexander Heinzel, Bernd J Krause, Thomas Krause, Markus Mitterhauser, Wilfried Sonnenschein, Lisa Bodei, Roberto C Delgado-Bolton, Michael Gabriel
Radium Ra-223 dichloride (radium-223, Xofigo®) is a targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. Radium-223 is the first targeted alpha therapy in this indication providing a new treatment option, with evidence of a significant survival benefit, both in overall survival and in the time to the first symptomatic skeletal-related event. The skeleton is the most common metastatic site in patients with advanced prostate cancer...
December 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29232987/radium-223-international-early-access-program-results-from-the-spanish-subset
#11
Joan Carles, Mª José Méndez, Álvaro Pinto, Mª Isabel Sáez, José A Arranz, Pablo Maroto, Pilar López-Criado, Begoña Mellado, Jesús García Donas, Susana Hernando, Luís León, Aránzazu González Del Alba, Núria Laínez, Emilio Esteban, Gaspar Reynés, José L Pérez-Gracia, Josep R Germà, Marta López-Brea, Begoña Pérez-Valderrama, Cristina Moretones, Daniel Castellano
AIM: To report results from the Spanish subset included in the radium-223 international early access program (iEAP). PATIENTS & METHODS: Ninety patients with castration-resistant prostate cancer and bone metastases received radium-223 55 kBq/kg every 4 weeks for six cycles. RESULTS: The median time to disease progression was 8 months and to prostate-specific antigen progression was 4 months. The percentage of patients with ≥50% confirmed declines in prostate-specific antigen was 9%...
December 13, 2017: Future Oncology
https://www.readbyqxmd.com/read/29196208/eradicate-a-prospective-evaluation-combining-radium-223-dichloride-and-abiraterone-acetate-plus-prednisone-in-patients-with-castration-resistant-prostate-cancer
#12
Neal D Shore, Ronald F Tutrone, Neil F Mariados, Luke T Nordquist, Bryan A Mehlhaff, Karyn J Steere, Stacey S Harrelson
BACKGROUND: Multiple castration-resistant prostate cancer (CRPC) therapies are approved by the United States Food and Drug Administration. Radium-223 dichloride (Ra-223) with abiraterone acetate plus prednisone have different mechanisms of action and distinct off-target side-effect profiles. We prospectively investigated their combined safety, tolerability, and patient-reported outcome measures. PATIENTS AND METHODS: eRADicAte, an investigator-initiated, phase II trial, studied 31 patients with metastatic CRPC, from 5 United States uro-oncology research sites...
November 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29189490/excretion-and-whole-body-retention-of-radium-223-dichloride-administered-for-the-treatment-of-bone-metastases-from-castration-resistant-prostate-cancer
#13
Brenda E Pratt, Cecilia Hindorf, Sarah J Chittenden, Christopher C Parker, Glenn D Flux
OBJECTIVE: The aim of the study was to determine the fraction of administered activity that was excreted and retained by a small cohort of patients who each received treatment with radium-223 dichloride (Ra). Ra is an α-emitting radionuclide that has been approved for use in the treatment of bone metastases that are secondary to castration resistant prostate cancer. PATIENTS AND METHODS: Six patients received two weight-based administrations of Ra 6 weeks apart...
November 17, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29183960/radium-223-safety-efficacy-and-concurrent-use-with-abiraterone-or-enzalutamide-first-u-s-experience-from-an-expanded-access-program
#14
Oliver Sartor, Nicholas J Vogelzang, Christopher Sweeney, Daniel C Fernandez, Fabio Almeida, Andrei Iagaru, Alan Brown, Matthew R Smith, Manish Agrawal, Adam P Dicker, Jorge A Garcia, Jose Lutzky, Yu-Ning Wong, Oana Petrenciuc, Jeremy Gratt, Neal D Shore, Michael J Morris
BACKGROUND: In the phase III ALSYMPCA trial, metastatic castration-resistant prostate cancer (mCRPC) patients had few prior life-prolonging therapies. Following ALSYMPCA, which demonstrated radium-223 survival benefit, and before radium-223 U.S. commercial availability, an expanded access program (EAP) providing early-access radium-223 allowed life-prolonging therapies in current use. SUBJECTS, MATERIALS, AND METHODS: This phase II, open-label, single-arm, multicenter U...
November 28, 2017: Oncologist
https://www.readbyqxmd.com/read/29181271/radium-223-in-metastatic-hormone-sensitive-high-grade-prostate-cancer-initial-experience
#15
García-Pérez Francisco Osvaldo, Medina-Ornelas Sevastián Salvador, Santana-Ríos Zael, Sobrevilla-Moreno Nora
Our study evaluates the feasibility of compassionate exemption of Radium-223 (223Ra) treatment in metastatic hormone-sensitive high-grade prostate cancer (mHSHGPC) patients with concomitant androgen deprivation-therapy (ADT). Seven patients with mHSHGPC, were treated with six cycles of 223Ra plus ADT. All patients had undergone to 18F-NaF-PET/CT. A qualitative analyses of the 18F-NaF-PET/CT was performed in conjunction with Alkaline Phosphatase (ALP), Lactate-dehydrogenase (LDH) and Prostatic-Specific Antigen (PSA) values...
2017: American Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29174502/lymph-node-response-in-a-patient-with-metastatic-castration-resistant-prostate-cancer-treated-with-radium-223
#16
Darren M C Poon, Kenneth C W Wong
No abstract text is available yet for this article.
November 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29137877/immune-analysis-of-radium-223-in-patients-with-metastatic-prostate-cancer
#17
Joseph W Kim, Min Sun Shin, Youna Kang, Insoo Kang, Daniel P Petrylak
BACKGROUND: Radium223 (Ra223) delivers high-energy radiation to osteoblastic metastasis of prostate cancer, resulting in irreparable double-stranded DNA damage. The effects of Ra223 on CD8+ T cell subsets in patients with prostate cancer is unknown. PATIENTS AND METHODS: Fifteen men with metastatic prostate cancer with clinical indication for Ra223 without any autoimmune or immune deficiency conditions were enrolled. Patients received a course of Ra223 50 kBq/kg...
October 24, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29134562/seom-clinical-guidelines-for-the-treatment-of-metastatic-prostate-cancer-2017
#18
J Cassinello, J Á Arranz, J M Piulats, A Sánchez, B Pérez-Valderrama, B Mellado, M Á Climent, D Olmos, J Carles, M Lázaro
Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma...
November 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29101113/treatment-of-advanced-prostate-cancer-a-review-of-current-therapies-and-future-promise
#19
Semini Sumanasuriya, Johann De Bono
Despite many recent advances in the therapy for metastatic castration-resistant prostate cancer (mCRPC), the disease remains incurable, although men suffering from this disease are living considerably longer. In this review, we discuss the current treatment options available for this disease, such as taxane-based chemotherapy, the novel hormone therapies abiraterone and enzalutamide, and treatments such as radium-223 and sipuleucel-T. We also highlight the need for ongoing research in this field, because, despite numerous recent advances, the prognosis for mCRPC remains poor...
November 3, 2017: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/29100167/early-identification-and-intervention-matters-a-comprehensive-review-of-current-evidence-and-recommendations-for-the-monitoring-of-bone-health-in-patients-with-cancer
#20
REVIEW
Thomas Brodowicz, Peyman Hadji, Daniela Niepel, Ingo Diel
Bone metastases are common in patients with advanced solid tumors, and many individuals experience debilitating skeletal-related events (SREs; e.g. pathologic fracture, hypercalcemia, radiotherapy or surgery to bone, and spinal cord compression). These events substantially affect disease outcomes, including survival and quality of life, and healthcare systems. Plain radiography is the most widely used imaging modality for the detection of bone metastases; skeletal scintigraphy, computed tomography, positron emission tomography and magnetic resonance imaging offer greater sensitivity but their use in routine practice is restricted by high costs and limited availability...
October 18, 2017: Cancer Treatment Reviews
keyword
keyword
82605
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"